Alzheimer’s Disease is an irreversible chronic disorder - 1 in 3 seniors die with Alzheimer’s or another form of dementia. With those two shocking facts, global research on cannabis and the human Endocannabinoid System continues to reveal potential use of cannabis to address the catastrophic impact of Alzheimer’s Disease (AD) on our families.
![Writing in the British Journal of Pharmacology in 2009, investigators at Ireland's Trinity College Institute of Neuroscience concluded, "(C]annabinoids offer a multi-faceted approach for the treatment of Alzheimer's disease by providing neuroprotection and reducing neuroinflammation, whilst simultaneously supporting the brain's intrinsic repair mechanisms by augmenting neurotrophin expression and enhancing neurogenesis. Manipulation of the cannabinoid pathway offers a pharmacological approach for the treatment of AD that may be more efficacious than current treatment regimens." More recently, a 2020 review of the available preclinical literature concluded that cannabinoids possess the ability to mitigate both the neuroinflammation and oxidative stress associated with the onset of AD. Authors concluded: "Targeting the endocannabinoid system can be a promising strategy to develop an effective therapy for the management of AD. Furthermore, cannabinoids may demonstrate a safe and reliable low-cost therapy, with limited side effects. Future research is needed to investigate the use of cannabinoids for the treatment of AD in a clinical trial setting."](https://static.wixstatic.com/media/9d50b9_adb33843e39d4c8c89e4a4e584878f86~mv2.png/v1/fill/w_980,h_1260,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/9d50b9_adb33843e39d4c8c89e4a4e584878f86~mv2.png)
What Does Research Say About the Endocannabinoid System and Alzheimer’s Disease?
A recent research article published on the US National Library of Medicine and National Institues of Health in 2020 offers preclinical literature that cannabinoids possess the ability to mitigate both the neuroinflammation and oxidative stress associated with the Alzheimer’s Disease.
"Targeting the endocannabinoid system can be a promising strategy to develop an effective therapy for the management of AD. Furthermore, cannabinoids may demonstrate a safe and reliable low-cost therapy, with limited side effects. Future research is needed to investigate the use of cannabinoids for the treatment of AD in a clinical trial setting." Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer’s Disease
Alzheimer’s Disease Fact, Figures and Cannabis
More than 6 million Americans are reported to be living with AD
16% Increase in deaths related to AD and dementia during pandemic
AD kills more seniors than breast cancer and prostate cancer combined
7.3% drop in heart disease deaths (2000-2019)
145% increase in deaths from AD (2008-2019)
$355 billion: healthcare cost in the USA - AD and dementia (2021)
Questions About Medical Cannabis and Alzheimer’s Disease?
Let’s talk! OMNI Medical has a years of experience working with medical cannabis, patients, CBD, THC, and is a multiple state operator.
What is Your Endocannabinoid System Telling You?
OMNI Medical Services recommends Endocanna Health's DNA kits for medical cannabis patients. Always speak with a qualified licensed medical professional for medical advice.
Includes Your Own Secure Online Health Portal!
57 different genetic Trait Reports in 12 different categories.
Precision cannabinoid ratios and terpene profile matching.
Personalized drug-to-drug interaction alerts.
Cannabinoid risks/benefits for your specific genotype.
Personalized wellness plan.
Endo·Aligned formulations suggestions.
Endo·Aligned Trusted Formulations marketplace.
Geolocation product finder.
Endo-DNA Collection Kit and Endo-Decoded Report: $199.00 Order online with OMNI for only $159.20! Save $39.80
OMNI Medical Services is glad to help answer your questions about medical cannabis and your healthcare options.
Call (888) 470-0008 now or request a call back to learn more.
Comments